Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.
Anthony W TolcherJoshua D BrodyNishanthan RajakumaraswamyMichelle R KuhneTorsten TroweAnees M DaukiShantheri PaiLing HanKai-Wen LinMichael PetrarcaShivaani KummarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
GS-3583 was relatively well tolerated and induced dose-dependent expansion of cDCs in the periphery of patients with advanced solid tumors. However, development of a second primary malignancy provides a cautionary tale for the FLT3 agonist mechanism.